Sanofi targets 70% of endotoxin tests without horseshoe crab blood by 2030
SNY•Sanofi plans to use synthetic alternatives in 70% of quality-control endotoxin tests by year-end 2030 and use synthetic testing methods for all new product launches by then. A nature-risk assessment identified four critical natural raw materials, with expected financial exposure described as negligible.
1. Synthetic testing target
Sanofi plans to replace horseshoe crab blood-derived reagents with synthetic alternatives in 70% of quality-control endotoxin tests by year-end 2030. All new product launches will use synthetic testing methods by the same deadline. The company’s nature-risk assessment identified four critical natural raw materials across its operations and value chain, with expected financial exposure described as negligible.
